Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the schizophrenia drugs market?

The market size for schizophrenia drugs has seen sturdy growth in the past few years. The market is projected to expand from $7.96 billion in 2024 to $8.49 billion in 2025, indicative of a compound annual growth rate (CAGR) of 6.6%. This expansion during the historic phase was fueled by factors such as the development of newer medicines like second and third-generation antipsychotics, a surge in cases of mental disturbances and schizophrenia, increased consciousness regarding mental health, a rise in mental health awareness initiatives from government and non-government bodies, and growth in the geriatric population numbers.

What will be the schizophrenia drugs market size in the future?

The market for schizophrenia drugs is projected to experience robust growth in the coming years, with an expected value of $10.85 billion by 2029, and a compound annual growth rate (CAGR) of 6.3%. The anticipated growth during the forecast period is attributed to factors such as the rising demand for more efficient treatment results, an uptick in research and development for improved antipsychotic drugs, product introductions and approvals, increasing investment on research for new mental health pharmaceuticals, enhanced insurance policies covering mental health treatments, as well as government initiatives and backing. Significant trends expected during this forecast period include the creation of long-lasting injectable preparations, the advent of digital technologies like mobile applications and wearables, new drugs aiming at glutamatergic pathways, the application of genetic and biomarker research, and an increased emphasis on additional therapies.

Get your schizophrenia drugs market report here!

https://www.thebusinessresearchcompany.com/report/schizophrenia-drugs-global-market-report

What main drivers are fueling expansion in the schizophrenia drugs market?

The escalating occurrence of schizophrenia is projected to stimulate the expansion of the market for schizophrenia drugs. Schizophrenia is a prolonged mental disorder characterized by distorted thinking, perceptions, emotions, and behavior, typically manifesting as hallucinations and delusions. This heightened incidence of schizophrenia is due to factors like genetic susceptibility, environmental triggers, substance misuse, and irregularities in brain chemistry. Drugs for schizophrenia effectively manage the symptoms, lessening the toll of the disorder on daily life and boosting overall treatment results. For example, the National Library of Medicine reported in February 2024 that the presence of schizophrenia and related psychotic disorders spanned 0.25% to 0.64% of the US populace. Moreover, the British Columbia Schizophrenia Society stated in January 2024 that schizophrenia is a leading cause of hospitalization for mental conditions, equating to 19.9% of all hospital admissions and 30.9% of admissions to psychiatric hospitals. Consequently, the mounting cases of schizophrenia will fuel the development of the schizophrenia drugs market.

What key areas define the segmentation of the global schizophrenia drugs market?

The schizophrenia drugs market covered in this report is segmented –

1) By Therapeutic Class: Second Generation, Third Generation, Other Therapeutic Classes

2) By Treatment: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Second Generation: Risperidone, Olanzapine, Quetiapine, Aripiprazole, Paliperidone, Ziprasidone, Others

2) By Third Generation: Brexpiprazole, Cariprazine, Others

3) By Other Therapeutic Classes: First-Generation Antipsychotics, Combination Therapies, Others

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20948&type=smp

Who are the dominant players expanding their reach in the schizophrenia drugs market?

Major companies operating in the schizophrenia drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co., Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., UCB S.A., Sun Pharmaceutical Industries Ltd., AbbVie Inc., H. Lundbeck A/S, Cipla Ltd., Lupin Limited, Alkermes plc, Vanda Pharmaceuticals Inc., Sumitomo Pharma Co. Ltd., Mylan NV, Otsuka Pharmaceutical Co. Ltd., Reviva Pharmaceuticals Holdings Inc., Lifegenix, Flagship Biotech International Pvt. Ltd.

How are evolving market trends shaping schizophrenia drugs Strategies?

Major companies operating in the schizophrenia drugs market are focused on developing advanced products, such as schizophrenia oral medication, to streamline and enhance patient care and treatment outcomes. Oral medications for schizophrenia are drugs taken by mouth to treat the disorder’s symptoms, often consisting of antipsychotics that aid in stabilizing mood, thoughts, and perceptions. For instance, in September 2024, Bristol Myers Squibb, a US-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approved Cobenfy, a groundbreaking oral medication designed to treat schizophrenia in adults. This innovative drug combines xanomeline and trospium chloride, marking a significant departure from traditional antipsychotics by targeting cholinergic receptors instead of dopamine receptors. This novel approach has the potential to provide relief from symptoms such as delusions and disorganized thinking while reducing the common side effects associated with older antipsychotic medications, positioning Cobenfy as a promising alternative in the schizophrenia treatment landscape.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20948

Which regions are emerging as leaders in the schizophrenia drugs market?

North America was the largest region in the schizophrenia drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the schizophrenia drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Hepatitis Drugs Global Market Report 2025

https://thebusinessresearchcompany.com/report/hepatitis-drugs-global-market-report

Local Anesthesia Drugs Global Market Report 2025

https://thebusinessresearchcompany.com/report/local-anesthesia-drugs-global-market-report

Non-Steroidal Anti-inflammatory Drugs Global Global Market Report 2025

https://thebusinessresearchcompany.com/report/non-steroidal-anti-inflammatory-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: